Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Bone metabolic marker; recent progress].

Masaaki Inaba1

  • 1Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine.

Clinical Calcium
|January 7, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Author's Reply to the Letter to the Editor: Is the "Nutritional Risk Index for Japanese Hemodialysis" Validated as a Nutritional and Prognostic Indicator?

Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation·2024
Same author

Association of Nutritional Risk Index With Infection-Related Hospitalization and Death After Hospitalization in Patients Undergoing Maintenance Hemodialysis.

Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation·2024
Same author

Evolution of cooperation in multiplex networks through asymmetry between interaction and replacement.

Scientific reports·2023
Same author

Serum Fibroblast Growth Factor 23 Levels are Associated with Vascular Smooth Muscle Dysfunction in Type 2 Diabetes.

Journal of atherosclerosis and thrombosis·2023
Same author

Associations of time-dependent changes in phosphorus levels with cardiovascular diseases in patients undergoing hemodialysis: results from the Japan Dialysis Active Vitamin D (J-DAVID) randomized clinical trial.

Clinical kidney journal·2022
Same author

Effects of alfacalcidol on cardiovascular outcomes according to alkaline phosphatase levels in the J-DAVID trial.

Scientific reports·2022

Bone markers supplement bone mineral density (BMD) tests for osteoporosis. They predict future BMD loss and assess fracture risk independently of BMD, aiding treatment selection and monitoring drug effectiveness.

Area of Science:

  • Biochemistry
  • Endocrinology
  • Orthopedics

Context:

  • Osteoporosis diagnosis and treatment rely on bone mineral density (BMD) measurements.
  • Bone markers offer complementary information to BMD.
  • The clinical utility of bone markers is increasingly recognized.

Purpose:

  • To evaluate the role of bone markers in osteoporosis management.
  • To explore the predictive value of bone markers for fracture risk.
  • To assess the effectiveness of osteoporosis therapies using bone markers.

Summary:

  • Bone markers aid in predicting future BMD reduction.
  • They assess fracture risk independently of BMD.
  • Bone markers allow for earlier evaluation of drug efficacy compared to BMD measurements.

Related Experiment Videos

  • Findings on raloxifene suggest fracture protection may be independent of BMD changes.

    • Impact:

    • Bone markers provide a valuable tool for personalized osteoporosis treatment strategies.
    • They enable timely adjustments to therapeutic regimens.
    • Understanding fracture risk independent of BMD enhances patient care and outcomes.